In addition, we found that PSORI-CM02 effectively protected imiquimod-induced psoriasis-like mice from skin lesions by decreasing TNF-α, IL-6, and IL-17 levels, regulating the oxidant/antioxidant status, altering the balance between Th17 response and CD4+ Foxp3+ Treg generation, and inhibiting NF-κB signaling pathway. Here, FOXP3 is linked to psoriasis.